WHO’s Access to Medicines and Health Product Division (WHO/MHP) confirms that, as of 01 January 2020, all activities and functions within the scope of WHO’s Diagnostics and Laboratory Technology Unit of the Department of Essential Health Technologies (WHO/EHT/DLT) are now carried out by WHO’s Access to Medicines and Health Products Division (MHP), namely through the Regulation and Prequalification Department. WHO’s MHP division is not a new entity or separate organization, but a restructured office that remains part of WHO. WHO/MHP confirms that WHO/MHP is bound by the commitments made by WHO/EHT/DLT to protect FDA-provided non-public information in accordance with the mutual confidentiality arrangement entered into between WHO/EHT/DLT and FDA, effective 10 October 2011 (the “2011 Arrangement”), and that WHO/MHP will continue to protect any non-public information previously shared by FDA with WHO/EHT/DLT in accordance with the provisions of the 2011 Arrangement.  For the avoidance of doubt, FDA shall also continue to treat and protect—in accordance with the provisions of the 2011 Arrangement—any non-public or confidential information that has been or will be provided by WHO/MHP thereunder.